An evaluation of the role of locoregional treatments\ua0for the management of in-transit melanoma metastases by Read, Tavis
1 = SSM  2 = Nodular   3 = Acral Lentiginous  4 = LMM  
5= Desmoplastic  6 = Not Available  7 = Other: …………………………………………… 
 
1 = No 
2 = Yes 
3 = NA 
1 = Nil 
2 = 1 
3 = 2-5 
4 = >5 
5 = NA 
 
 
2 + Yes 
BRAF Status  1 = Positive   2 = Negative   3 = Not Tested   
1 = Regional LN 
2 = Distant site 
3 = Both 
 
Yes 
No 
1 = Yes 
2 = No 
3 = NA 
[I – V] 
1 = Yes  2 = No  3 = NA 1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
 
IN-TRANSIT MELANOMA DATABASE  
 
ID NO: …………    
 
Date 1st Clinic Review: ……………….. 
  
Date Last Clinic Review: ………………..  
 
PRIMARY DEMOGRAPHICS: 
Unknown Primary:              1 = Yes 
       2 = No 
PATHOLOGY:  Date of Primary Diagnosis: ............................................................. 
 
Clinico-pathological Classification: 
 
THICKNESS: …………………. mm 
 
DATE OF DEATH: …………………… 
            MITOSES RECORDED 
DEATH DUE TO MM SEQUELAE:        
 
CLARK’S LEVEL:          ULCERATION:          LVI:                    REGRESSION:         MICROSATELLITES:           MITOSES:  
                     
 
 
 
T STAGE: 
 
PRIMARY SITE: 
 
1. Head 
 
 
 
 
2. Limbs 
 
 
 
 
3. Trunk 
 
          
METASTASES: 
         Site: …………………………….. Date Detected:…………….. 
1.          Site: …………………………….. Date Detected:…………….. 
        Site: …………………………….. Date Detected:…………….. 
 
REFERRAL SOURCE: 
 
 
 
 
 
1 = Arm 
2 = Forearm 
3 = Hand 
4 = Thigh  
5 = Leg 
6 = Foot 
 
1 = Anterior 
2 = Posterior 
3 = Midline 
 
1 = Above umbilicus 
2 = Below umbilicus 
 
2 + Yes 
1 = Scalp 
2 = Face 
3 = Neck 
 
 
1 = Right 
2 = Left 
3 = Central 
 
1A = <1.0mm No ulcer   2A = 1-2mm No Ulcer   3A = 2-4mm No Ulcer   4A = >4mm No Ulcer   0 = Unknown 
1B = <1.0mm Ulcer         2B = 1-2 mm Ulcer        3B = 2-4 mm Ulcer        4B = >4mm Ulcer         Is = In-situ 
 Surname: First Name: 
 DOB URN: 
 Address: 
 
 Phone: 
 Age: Sex: 
1 = Upper 
2 = Lower 
 
1 = Right 
2 = Left 
 
1 = Right 
2 = Left 
3 = Central 
 
1 = Primary Care Physician or GP 
2 = Rural (Non-metropolitan) Hospital 
3 = Specialist 
4 = Melanoma Clinic 
5 = NA 
 
2 
 
1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
 
IN-TRANSIT MELANOMA DATABASE  
 
PRIMARY MANAGEMENT:                    
 
 
WLE:           SLNB:                                        SLNB +                       MARGIN of WLE:  …….. (mm) 
 
 
LYMPH NODE DISSECTION:              NUMBER NODES POSITIVE:   IMMEDIATE RECONSTRUCTION 
 
 
 
 
Number + / Total: …………………………….. Date of LNDx: …………………………….. 
 
DATE OF 1ST LOCAL RECURRENCE/ SATELLITE / IN-TRANSIT (SINCE PRIMARY): _______________ 
 
DEFINITION:  
 
 
 
SITE OF RECURRENCE: 
   
 
 
 
 
NUMBER OF NODULES: 
 
 
 
 
 
TISSUE DEPTH: 
 
                         
 Dermal     Subcutaneous           
         
          
     
 
 Involving Deep Fascia  Below Deep Fascia     
 
SIZE: 
 
Smallest: ……… 
Largest: ……… 
 
 
Describe:  ............................................. 
 
 
 
1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
1 = Yes 
2 = No 
3 = NA 
1 = Local Recurrence (within primary scar) 
2 = Satellite 
3 = In-transit  
4 = Both  
5 = Other State: …………………. 
1 = Upper Limb 
2 = Lower Limb 
3 = Head / neck 
4 = Torso 
1 = 1-4  4 = 15-19 
2 = 5-9  5 = >20 
3 = 10-14 6 = Data N/A 
 
1 = Yes 
2 = No 
3 = NA 
 
 
1 = 1-4  4 = 15-19 
2 = 5-9  5 = >20 
3 = 10-14 6 = Data N/A 
 
1 = STSG  4 = Pedicled or FTT 
2 = FTSG   5 = Data N/A 
3 = Local flap 6 = Other ………………. 
 
 
1 = Arm 
2 = Forearm 
3 = Hand 
4 = Thigh  
5 = Leg 
6 = Foot 
 
 
1 = Right 
2 = Left 
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IN-TRANSIT MELANOMA DATABASE  
 
OPERATION DETAILS: 
 
SURGERY: 
 
1. Date of Surgery: ……………….. No. of Lesions Excised: 
 
 
Margins involved:  
 
Procedure: …………………………………… 
 
2. Date of Surgery: ……………….. No. of Lesions Excised: 
 
 
Margins involved:  
 
Procedure: …………………………………… 
 
3. Date of Surgery: ……………….. No. of Lesions Excised: 
 
 
Margins involved:  
 
Procedure: …………………………………… 
 
4. Date of Surgery: ……………….. No. of Lesions Excised: 
 
 
Margins involved:  
 
Procedure: …………………………………… 
 
5. Date of Surgery: ……………….. No. of Lesions Excised: 
 
Margins involved:  
 
Procedure: …………………………………… 
 
6. Date of Surgery: ……………….. No. of Lesions Excised:  
 
 
Margins involved:  
 
 
Procedure: …………………………………… 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
1 = Yes 
2 = No 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
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IN-TRANSIT MELANOMA DATABASE  
 
 
7. Date of Surgery: ……………….. No. of Lesions Excised: 
 
 
Margins involved:  
 
Procedure: …………………………………… 
 
8. Date of Surgery: ……………….. No. of Lesions Excised: 
 
Margins involved:  
 
Procedure: …………………………………… 
 
9. Date of Surgery: ……………….. No. of Lesions Excised: 
 
 
Margins involved:  
 
Procedure: …………………………………… 
 
10. Date of Surgery: ……………….. No. of Lesions Excised: 
 
 
Margins involved:  
 
Procedure: …………………………………… 
 
 
SURGICAL CLOSURE: 
 
 
Primary Closure:      Procedure Numbers: ………… 
 
 
 
Delayed Closure:      Procedure Numbers: ………… 
 
 
 
Reconstruction:  
 
 
Procedure Numbers: …………  
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 =  STSG/FTSG 
2 =  Local Flap 
3 =  Pedicled Flap 
4 =  Free Tissue Transfer 
5 =  Other 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
 
 
1 =  < 1mm 
2 =     1-10mm  
3 =  > 10mm 
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IN-TRANSIT MELANOMA DATABASE  
PV-10 DETAILS: 
 
PV-10 TREATMENT: 
 
1. Date of Treatment: ....................................   
 
 Size of Smallest Lesion: .............mm  Size of Largest Lesion: .................mm 
 
 Total Volume of PV-10: ..............mls  No. of Lesions Treated: ………..      
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
 
 Erythema:          Blistering:      Lymphoedema:  
 
 
 Distant:         Other Reaction / 
 Oedema         Symptoms:        
 
2. Date of Treatment: ....................................   
 
 Size of Smallest Lesion: .............mm  Size of Largest Lesion: .................mm 
 
 Total Volume of PV-10: ..............mls  No. of Lesions Treated: ………..      
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
 
 Erythema:          Blistering:      Lymphoedema:  
 
 
 Distant:         Other Reaction / 
 Oedema         Symptoms:        
 
3. Date of Treatment: ....................................   
 
 Size of Smallest Lesion: .............mm  Size of Largest Lesion: .................mm 
 
 Total Volume of PV-10: ..............mls  No. of Lesions Treated: ………..      
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
 
 
 Erythema:          Blistering:      Lymphoedema:  
 
 
 Distant:         Other Reaction / 
 Oedema         Symptoms:        
 
 
 
1 = Yes 
2 = No 
 
 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
3 = State…………… 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
SIDE EFFECTS:  
 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
3 = State…………… 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
SIDE EFFECTS:  
 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
3 = State…………… 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
SIDE EFFECTS:  
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IN-TRANSIT MELANOMA DATABASE  
 
RADIATION DETAILS: 
 
RADIATION TREATMENT: 
 
 
1. Date of Treatment: ....................................  No. of Lesions Treated: 
 
Size of Smallest Lesion: .............mm  Size of Largest Lesion: .................mm 
 
Dose of Radiation: ..........Gy/...............Fr  Date Completed: ................................... 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
Indication: ................................... 
 
2. Date of Treatment: ....................................  No. of Lesions Treated: 
 
Size of Smallest Lesion: .............mm  Size of Largest Lesion: .................mm 
 
Dose of Radiation: ..........Gy/...............Fr  Date Completed: ................................... 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
Indication: ................................... 
 
3. Date of Treatment: ....................................  No. of Lesions Treated: 
 
Size of Smallest Lesion: .............mm  Size of Largest Lesion: .................mm 
 
Dose of Radiation: ..........Gy/...............Fr  Date Completed: ................................... 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
Indication: ................................... 
 
 
4. Date of Treatment: ....................................  No. of Lesions Treated: 
 
Size of Smallest Lesion: .............mm  Size of Largest Lesion: .................mm 
 
Dose of Radiation: ..........Gy/...............Fr  Date Completed: ................................... 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
Indication: ................................... 
  
1 = Yes 
2 = No 
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1 = Yes 
2 = No 
3 = NA 
 
IN-TRANSIT MELANOMA DATABASE  
ISOLATED LIMB DETAILS: 
 
ISOLATED LIMB INFUSION: 
 
RADIOLOGY:   Date: …………….. 
  
Site of Insertion: 
  
 
Problems:                           Cannula Size:  Artery: …………(Fr) Vein: ………….(Fr) 
 
LIMB DETAILS: 
Total Limb Volume: ………(Litres) Volume To Perfuse: ……….. (Litres) 
 
Foot/Hand Excluded:    Calculated Melphalan Dose: ………….. (mg) 
 
REGIONAL LYMPH NODE: Previous LNDx:    LNDx with Isolated Limb Infusion:              
 
PROCEDURE: 
 
Anaesthetic:      Volume of Perfusate: …………. (mLs)  
 
Time to Infuse Perfusate: …………. (mins)  Time for Circulation: …………. (mins) 
 
Total Treatment Time: …………. (mins)  Total Torniquet Time: …………. (mins) 
 
Total Volume Washout: …………. (mLs)  Total Volume Discarded: …………. (mLs) 
 
TEMPERATURES 
 
COMPLICATIONS: 
Acute Limb Complication: 
 
Wieberdink Grade:              
 
 
 
 
 
Vascular Complications: 
 Haematoma:  Bleeding:    Arterial Occlusion: 
 
 Venous Occlusion:            Compartment Syndrome: 
         
Elevated CPK:              If Yes, Number of Days Elevated:       Highest Level: …………. 
 
 
TIME (MINS) SKIN SUBCUTANEOUS MUSCLE 
0    
5    
10    
15    
1 = R) Groin Artery    2 = L) Groin Artery    3 = R) Axilla Artery 
4 = L) Axilla Artery     5 = R) Groin Vein      6 = L) Groin Vein 
7 = R) Axilla Vein       8 = L) Axilla Vein 
 
1 = Yes  State: ……………… 
2 = No                    
1 = Yes 
2 = No 
1 = General 
2 = Regional 
1 =Yes 
2 = No 
1 = No subjective or objective oedema or reaction 
2 = Slight erythema and/or oedema 
3 = Considerable erythema and/or oedema with some blistering, slightly obstructed mobility 
4 = Extensive epidermolysis and/ or obvious damage to deep tissues causing functional disturbance, 
       Threatening or manifest compartment syndrome 
5 = Severe reaction (may necessitate amputation) 
 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
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IN-TRANSIT MELANOMA DATABASE  
DPCP DETAILS: 
 
DCPC Treatment:    NUMBER OF NODULES: 
 
DISEASE PHENOTYPE: …………………………… EPIDERMOTROPIC/NODULAR/MIXED/BULKY/NA  
 
PREVIOUS TREATMENTS: ………………………… 
 
SITE OF LESIONS: 
 
 
DATE OF SENSITISATION: ……………..          
DATE OF FIRST TREATMENT: ……………..  DATE OF LAST TREATMENT: …………….. 
 
FACT-M HEALTH RELATED QUALITY OF LIFE ASSESSMENT (BASELINE): …………….. 
FACT-M HEALTH RELATED QUALITY OF LIFE ASSESSMENT (INTERVALS, MID-POINT): …………….. 
FACT-M HEALTH RELATED QUALITY OF LIFE ASSESSMENT (FINAL TREATMENT): …………….. 
 
TOTAL NUMBER OF TREATMENTS (COMPLETED): …………….. 
 
1. Date of Treatment: ....................................  No. of Lesions Treated: 
 
 Smallest Lesion Diameter: ............. mm  Largest Lesion Diameter: ................. mm 
 
Dose of DPCP: [Minimum]: .................  [Maximum]: .................  [Maintenance]: ................. 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
 
2. Date of Treatment: ....................................  No. of Lesions Treated: 
 
 Smallest Lesion Diameter: ............. mm  Largest Lesion Diameter: ................. mm 
 
Dose of DPCP: [Minimum]: .................  [Maximum]: .................  [Maintenance]: ................. 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
SIDE EFFECTS:  
 Erythema:          Blistering:        Oedema:  
 
 
 Conjunctivitis:        Influenza-like      A        Allergic  
           Symptoms:       Reaction: 
 
SEVERE TREATMENT-RELATED ADVERSE EVENTS: ……………… 
 
DATE OF RECURRENCE: ……………… DATE OF PROGRESSION: ……………… 
SITE OF RECURRENCE:  
 
 
1 = Yes 
2 = No 
1 = Leg 
2 = Arm 
3 = Head 
4 = Torso 
1 = Right 
2 = Left 
1 = 0-4  4 = 15-19 
2 = 5-9  5 = >20 
3 = 10-14 6 = Data N/A 
 
1 = Arm 
2 = Forearm 
3 = Hand 
4 = Thigh  
5 = Leg 
6 = Foot 
 
1 = Upper Limb 
2 = Lower Limb 
3 = Head / neck 
4 = Torso 
1 = Arm 
2 = Forearm 
3 = Hand 
4 = Thigh  
5 = Leg 
6 = Foot 
 
1 = Yes 
2 = No 
 1 = Yes 
 2 = No 
1 = Yes 
2 = No 
   1 = Yes 
   2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Right 
2 = Left 
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IN-TRANSIT MELANOMA DATABASE  
IMIQUIMOD DETAILS: 
 
IMIQUIMOD TREATMENT:        NUMBER OF                    NODULES: 
      
 DISEASE PHENOTYPE: …………………………… EPIDERMOTROPIC/NODULAR/MIXED/BULKY/NA  
 
PREVIOUS TREATMENTS: ………………………… 
 
SITE OF LESIONS: 
 
 
DATE OF SENSITISATION: ……………..          
DATE OF FIRST TREATMENT: ……………..  DATE OF LAST TREATMENT: …………….. 
 
FACT-M HEALTH RELATED QUALITY OF LIFE ASSESSMENT (BASELINE): …………….. 
FACT-M HEALTH RELATED QUALITY OF LIFE ASSESSMENT (INTERVALS, MID-POINT): …………….. 
FACT-M HEALTH RELATED QUALITY OF LIFE ASSESSMENT (FINAL TREATMENT): …………….. 
 
1. Date of Treatment: ....................................  No. of Lesions Treated: 
 
 Smallest Lesion Diameter: ............. mm  Largest Lesion Diameter: ................. mm 
 
 Dose of Imiquimod: ............. Concentration  Frequency: ............. 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
2. Date of Treatment: ....................................  No. of Lesions Treated: 
 
 Smallest Lesion Diameter: ............. mm  Largest Lesion Diameter: ................. mm 
 
 Dose of Imiquimod: ............. Concentration  Frequency: ............. 
 
Lesion Response: No. of CR: ………..       No. of PR: ………..     No. of SD: ………..     No. of PD: ……….. 
 
SIDE EFFECTS:  
 Erythema:          Blistering:        Oedema:  
 
 
 Conjunctivitis:        Influenza-like      A        Allergic  
           Symptoms:       Reaction: 
 
SEVERE TREATMENT-RELATED ADVERSE EVENTS: ……………… 
 
DATE OF RECURRENCE: ……………… DATE OF PROGRESSION: ……………… 
SITE OF RECURRENCE:  
 
 
 
 
 
 
 1 = Yes 
 2 = No 
 
 
1 = 0-4  4 = 15-19 
2 = 5-9  5 = >20 
3 = 10-14 6 = Data N/A 
 
1 = Leg 
2 = Arm 
3 = Head 
4 = Torso 
1 = Right 
2 = Left 
1 = Arm 
2 = Forearm 
3 = Hand 
4 = Thigh  
5 = Leg 
6 = Foot 
 
1 = Arm 
2 = Forearm 
3 = Hand 
4 = Thigh  
5 = Leg 
6 = Foot 
 
1 = Upper Limb 
2 = Lower Limb 
3 = Head / neck 
4 = Torso 
1 = Yes 
2 = No 
 1 = Yes 
 2 = No 
1 = Yes 
2 = No 
   1 = Yes 
   2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Right 
2 = Left 
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1 = Yes 
2 = No 
 
IN-TRANSIT MELANOMA DATABASE  
 
FURTHER TREATMENTS: COMPLETE ONLY IF PATIENTS HAS HAD TREATMENT SINCE ABOVE MODALITIES 
 
Further Treatment: 
 
 
Local:                                
 
Local Treatment Type:   Excision:    XRT:             Diathermy: 
 
      ILI:                    Site: Imi/              PV-10 
DPCP               
 
Systemic: 
 
 
Systemic Treatment Type:        Chemotherapy:          Targeted / Immunotherapy:  
 
                                 
 
OTHER TREATMENTS: COMPLETE ONLY IF PATIENT HAD FURTHER TREATMENT NOT DESCRIBED ABOVE 
 
Other Treatment: 
 
 
Local:                                
 
Local Treatment Type:  ……………………   E.g. Other intra-lesional injection, electro-chemablation, laser, T-VEC 
 
Further details: ……………………             
 
 
Systemic: 
 
 
Systemic Treatment Type: ……………………   E.g. Chemotherapy, Targeted / Immunotherapy, NY-ESO,    
Further details: ……………………             
 
DISEASE RESPONSE FROM OTHER TREATMENTS: SINCE FINAL TREATMENT 
 
 
 
Complete Response:               Partial Response: 
 
 
 
 
Stable Disease:                Progression: 
 
 
 
 
 
 
 
 
 
1 = Yes 
2 = No  1 = Yes 
2 = No 
 
1 = Yes 
2 = No
 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
   Reduced Numbers by 30% 
     Reduced Size by 30% 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
Increased Size 
 
Increased Number 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
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1 = Yes 
2 = No 
 
IN-TRANSIT MELANOMA DATABASE  
 
CLINIC FOLLOW-UP: COMPLETE IN CLINIC DURING EACH REVIEW (PROSPECTIVELY) 
 
   DATE: …………… 
 
OVERALL DISEASE STATUS: 
 
 1 = Alive, no evidence of disease, 2 = Alive with local disease, 3 = Alive with distant disease,   
                            4 = Alive with both local & distant disease, 5 = Dead with disease, 6 = Dead without disease 
 
         
SIDE-EFFECT STATUS: 
 
SHORT TERM: COMPLETE FOR THE FIRST 6 MONTHS FOLLOWING LAST TREATMENT 
 
Erythema:          Oedema:                Pain:               Blisters/Desquamation               
 
 
LONG TERM: (COMPLETE EACH TIME) 
 
Functional Problems:   State: ………………………….       Lymphoedema: 
 
Treated Lesions 
 
 
Complete Response:             Time to Response:             
 
 
 
 
Partial Response: 
 
 
 
 
Stable Disease:             
 
 
 
 
Progression: 
 
 
 
Non-Treated Lesions (If Applicable): 
 
No. of Lesions CR:    No. of Lesions PR:  
 
 
 
No. of Lesions SD:    No. of Lesions PD: 
 
 
Number of New Lesions: ……………. 
 
 
CURRENT RESPONSE:  
 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
Grade 
1 - 4 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No Increased Size 
 
Increased Number 
1 = Yes 
2 = No 1 = Yes 
2 = No 
1 = Yes 
2 = No 
  Reduced Number by 30% 
   Reduced Size by 30% 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = 8 weeks 
2 = 12 weeks 
3 = 24 weeks 
4 = 36 weeks 
5 = 48 weeks 
1 = Complete Response 
2 = Partial Response 
3 = Stable Disease 
4 = Progressive Disease 
5 = Death 
6 = Loss to Follow-up 
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IN-TRANSIT MELANOMA DATABASE  
 
RETROSPECTIVE FOLLOW-UP FORM: FOR INDIVIDUAL TREATMENTS 
 
Date: …………… 
 
Previous Treatments: ……………. 
 
Last Treatment Type: …………….  
 
Number of Weeks Since Last Treatment: …………… 
 
 
Treated Lesions 
 
 
Complete Response:             Time to Response:             
 
 
 
 
 
 
Partial Response: 
 
 
 
 
 
Stable Disease:             
 
 
 
 
 
Progression: 
 
 
 
 
Non-Treated Lesions (If Applicable): 
 
 
No. of Lesions CR:     No. of Lesions PR:  
 
 
 
No. of Lesions SD:     No. of Lesions PD: 
 
 
 
Number of New Lesions: ……………. 
 
 
 
 
 
CURRENT RESPONSE:  
 
  
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
Increased Size 
 
Increased Number 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
  Reduced Number by 30% 
   Reduced Size by 30% 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = 8 weeks 
2 = 12 weeks 
3 = 24 weeks 
4 = 36 weeks 
5 = 48 weeks 
1 = Complete Response 
2 = Partial Response 
3 = Stable Disease 
4 = Progressive Disease 
5 = Death 
6 = Loss to Follow-up 
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IN TRANSIT MELANOMA DATABASE  
 
FINAL FOLLOW-UP FORM: OVERALL DISEASE RESPONSE 
 
Date: …………… 
 
Previous Treatment Types: ……………. 
 
Number of Weeks Since Last Treatment: …………… 
 
 
Treated Lesions 
 
 
Complete Response:             Time to Response:             
 
 
 
 
 
 
Partial Response: 
 
 
 
 
 
Stable Disease:             
 
 
 
 
 
Progression: 
 
 
 
 
Non-Treated Lesions (If Applicable): 
 
 
No. of Lesions CR:     No. of Lesions PR:  
 
 
 
No. of Lesions SD:     No. of Lesions PD: 
 
 
 
Number of New Lesions: ……………. 
 
 
OVERALL DISEASE STATUS: 
 
 1 = Alive, no evidence of disease, 2 = Alive with local disease, 3 = Alive with distant disease,   
                            4 = Alive with both local & distant disease, 5 = Dead with disease, 6 = Dead without disease 
 
 
 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
Increased Size 
 
Increased Number 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
  Reduced Number by 30% 
   Reduced Size by 30% 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
1 = 8 weeks 
2 = 12 weeks 
3 = 24 weeks 
4 = 36 weeks 
5 = 48 weeks 
